Table E5.
Sputum mediators for asthmatic patients and patients with COPD across the 3 identified biologic exacerbation clusters
| Cluster 1 |
Cluster 2 |
Cluster 3 |
ANOVA | ||||
|---|---|---|---|---|---|---|---|
| Asthmatic patients (n = 7) | Patients with COPD (n = 27) | Asthmatic patients (n = 10) | Patients with COPD (n = 17) | Asthmatic patients (n = 15) | Patients with COPD (n = 29) | ||
| IL-1β (pg/mL) | 2,914 (1,038-8,179) | 2,007 (1,253-3,215) | 59 (17-206) | 35 (16-79) | 72 (29-179) | 72 (36-146) | †‡ |
| IL-5 (pg/mL) | 1.0 (0.3-3.6) | 0.6 (0.4-0.8) | 10.4 (4.2-25.5) | 7.4 (4.9-11.2) | 1.7 (0.7-4.6) | 1.0 (0.6-1.7) | †‡ |
| IL-6 (pg/mL) | 243 (76-772) | 791 (453-1,381) | 47 (17-127) | 368 (237-571)∗ | 115 (41-319) | 689 (336-1,413)∗ | |
| IL-6R (pg/mL) | 1,327 (598-2,944) | 733 (506-1,061) | 396 (253-620) | 149 (104-214)∗ | 285 (150-542) | 130 (86-197)∗ | †‡ |
| IL-8 (pg/mL) | 16,605 (8,979-30,709) | 12,432 (9,419-16,408) | 3,662 (1,630-8,227) | 2,945 (2,029-4,274) | 3,428 (1,668-7,042) | 2,755 (1,688-4,495) | †‡ |
| IL-10 (pg/mL) | 39.3 (6.2-247.9) | 13.8 (8.2-23.3) | 1.9 (1.5-2.5) | 1.9 (1.6-2.3) | 17.7 (4.7-67.2) | 5.1 (2.7-9.3) | †‡ |
| IL-13 (pg/mL) | 10.0 (5.8-17.5) | 8.3 (7.7-9.1) | 14.3 (7.2-28.5) | 12.0 (8.8-16.2) | 11.2 (8.0-15.7) | 9.2 (7.8-10.8) | ‡ |
| CXCL10 (pg/mL) | 634 (108-3,734) | 115 (69-189)∗ | 663 (272-1,618) | 305 (173-537) | 3,363 (1,408-8,035) | 1,031 (444-2,392)∗ | †‡ |
| CXCL11 (pg/mL) | 13 (2-100) | 3 (2-5) | 34 (11-201) | 21 (9-49) | 269 (47-1,552) | 110 (35-354) | †‡ |
| CCL2 (pg/mL) | 539 (181-1,608) | 271 (189-388) | 210 (141-311) | 547 (329-909)∗ | 656 (289-1,491) | 717 (424-1,213) | ‡ |
| CCL3 (pg/mL) | 85.5 (7.7-948.3) | 90.7 (53.3-154.3) | 27.1 (12.9-56.9) | 67.3 (34.1-132.6) | 32.7 (11.4-93.3) | 80.2 (43.5-147.6) | |
| CCL4 (pg/mL) | 410 (56-2,995) | 1,401 (898-2,183) | 955 (410-2,223) | 1,688 (1,066-2,673) | 662 (242-1814) | 1,053 (576-1,925) | |
| CCL5 (pg/mL) | 54.9 (25.6-117.5) | 10.0 (6.9-14.3)∗ | 8.5 (3.6-20.1) | 3.2 (1.9-5.3)∗ | 22.2 (8.4-58.4) | 7.4 (4.2-13.0)∗ | †‡ |
| CCL13 (pg/mL) | 9.1 (6.6-12.7) | 11.3 (9.0-14.2) | 22.3 (12.1-40.8) | 36.4 (25.3-52.3) | 15.5 (9.2-26.2) | 18.7 (12.4-28.1) | ‡ |
| CCL17 (pg/mL) | 12.1 (6.3-23.5) | 3.7 (2.2-6.4) | 69.7 (27.4-177.7) | 71.8 (45.6-113.1) | 11.2 (6.4-19.6) | 10.4 (7.0-15.4) | †‡ |
| CCL26 (pg/mL) | 3.1 (1.1-9.0) | 2.1 (1.7-2.7) | 39.8 (16.6-95.2) | 20.4 (15.4-26.9) | 5.2 (2.4-11.3) | 3.5 (2.4-5.2) | †‡ |
| TNF-α (pg/mL) | 290.9 (90.2-937.5) | 109.0 (65.8-180.5) | 2.4 (1.0-5.7) | 2.6 (1.2-5.7) | 10.3 (2.7-37.9) | 14.2 (5.7-35.5) | †‡ |
| TNF-R1 (pg/mL) | 5,430 (3,932-7,499) | 5,643 (4,303-7,400) | 640 (311-1,314) | 860 (627-1,179) | 552 (267-1,144) | 898 (661-1,220) | †‡ |
| TNF-R2 (pg/mL) | 2,746 (1,715-4,398) | 1,785 (1,236-2,578) | 373 (173-801) | 330 (227-481) | 513 (190-1,385) | 377 (214-663) | †‡ |
| VEGF (pg/mL) | 2,880 (1,428-5,807) | 2,323 (1,829-2,950) | 1,372 (927-2,031) | 1,076 (812-1,426) | 1,099 (751-1,607) | 1,057 (889-1,257) | †‡ |
| IFN-γ (pg/mL) | 6.9 (1.6-30.9) | 0.6 (0.4-1.0)∗ | 0.3 (0.3-0.3) | 0.4 (0.3-0.4) | 5.4 (0.9-31.1) | 2.6 (1.0-6.9) | †‡ |
Data are presented as geometric means with 95% CIs. Values in boldface indicate statistical significance.
∗
Significant difference between asthmatic patients and patients with COPD within clusters.
†, ‡
Overall significant difference between clusters in asthmatic patients or patients with COPD, respectively.